Intercepting Smoking-Related Respiratory Disease: Finding Novel Markers Beyond the Lung

Joseph I. Bailey; Ravi Kalhan

doi:10.1016/j.chest.2021.12.637

Intercepting Smoking-Related Respiratory Disease: Finding Novel Markers Beyond the Lung

Joseph I. Bailey^*, Ravi Kalhan

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	867-868
Number of pages	2
Journal	CHEST
Volume	161
Issue number	4
DOIs	https://doi.org/10.1016/j.chest.2021.12.637
State	Published - Apr 2022

Funding

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: R. K. reports receiving personal fees from AstraZeneca, GlaxoSmithKline, Omron, and CVS Health, none related to the current work. None declared (J. I. B.).

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chest.2021.12.637

Cite this

@article{8ba01115f6ae4ca4a861d8daec953ccc,

title = "Intercepting Smoking-Related Respiratory Disease: Finding Novel Markers Beyond the Lung",

author = "Bailey, {Joseph I.} and Ravi Kalhan",

note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: R. K. reports receiving personal fees from AstraZeneca, GlaxoSmithKline, Omron, and CVS Health, none related to the current work. None declared (J. I. B.).",

year = "2022",

month = apr,

doi = "10.1016/j.chest.2021.12.637",

language = "English (US)",

volume = "161",

pages = "867--868",

journal = "CHEST",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Intercepting Smoking-Related Respiratory Disease

T2 - Finding Novel Markers Beyond the Lung

AU - Bailey, Joseph I.

AU - Kalhan, Ravi

N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: R. K. reports receiving personal fees from AstraZeneca, GlaxoSmithKline, Omron, and CVS Health, none related to the current work. None declared (J. I. B.).

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85126991608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126991608&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2021.12.637

DO - 10.1016/j.chest.2021.12.637

M3 - Editorial

C2 - 35396040

AN - SCOPUS:85126991608

SN - 0012-3692

VL - 161

SP - 867

EP - 868

JO - CHEST

JF - CHEST

IS - 4

ER -

Intercepting Smoking-Related Respiratory Disease: Finding Novel Markers Beyond the Lung

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this